{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:06:27Z","timestamp":1790957187301,"version":"4.1.0"},"reference-count":80,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1093\/schbul\/sbr004","type":"journal-article","created":{"date-parts":[[2011,3,22]],"date-time":"2011-03-22T04:19:49Z","timestamp":1300767589000},"page":"1003-1011","source":"Crossref","is-referenced-by-count":132,"title":["Pharmacological Augmentation Strategies for Schizophrenia Patients With Insufficient Response to Clozapine: A Quantitative Literature Review"],"prefix":"10.1093","volume":"38","author":[{"given":"Iris E.","family":"Sommer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke J. H.","family":"Begemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Temmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,3,21]]},"reference":[{"key":"key\n\t\t\t\t20170508185122_bib1","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/schbul\/23.4.663","article-title":"Evaluation of treatment-resistant schizophrenia","volume":"23","author":"Conley","year":"1997","journal-title":"Schizophr Bull"},{"key":"key\n\t\t\t\t20170508185122_bib2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/schbul\/14.4.515","article-title":"A selective review of recent North American long-term followup studies of schizophrenia","volume":"14","author":"McGlashan","year":"1988","journal-title":"Schizophr Bull"},{"key":"key\n\t\t\t\t20170508185122_bib3","first-page":"850","article-title":"Economic grand rounds: cost-effectiveness of clozapine for treatment-resistant schizophrenic patients","volume":"41","author":"Revicki","year":"1990","journal-title":"Hosp Community Psychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1192\/S0007125000293161","article-title":"Economics and schizophrenia: the real cost","volume":"25","author":"Davies","year":"1994","journal-title":"Br J Psychiatry Suppl"},{"key":"key\n\t\t\t\t20170508185122_bib5","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"5","author":"Kane","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib6","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1176\/appi.ajp.158.4.518","article-title":"Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials","volume":"158","author":"Chakos","year":"2001","journal-title":"Am J Psychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib7","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/schbul\/sbj067","article-title":"Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia","volume":"32","author":"Lewis","year":"2006","journal-title":"Schizophr Bull"},{"key":"key\n\t\t\t\t20170508185122_bib8","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am J Psychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib9","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2165\/00003088-200342070-00001","article-title":"What is an adequate trial with clozapine?","volume":"42","author":"Schulte","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t20170508185122_bib10","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1176\/ajp.151.12.1744","article-title":"Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome","volume":"151","author":"Lieberman","year":"1994","journal-title":"Am J Psychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib11","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1007\/BF00442563","article-title":"A prospective study of clozapine in treatment-resistant schizophrenic patients: i: Preliminary report","volume":"99","author":"Meltzer","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"key":"key\n\t\t\t\t20170508185122_bib12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0006-3223(00)01026-X","article-title":"Lilly Resistant Schizophrenia Study Group. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients eligible for treatment with clozapine","volume":"49","author":"Tollefson","year":"2001","journal-title":"Biol Psychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0920-9964(99)00153-X","article-title":"Cognitive behavioural psychotherapy for schizophrenia: a review of recent empirical studies","volume":"43","author":"Dickerson","year":"2000","journal-title":"Schizophr Res"},{"key":"key\n\t\t\t\t20170508185122_bib14","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/oxfordjournals.schbul.a006901","article-title":"When symptoms persist: clozapine augmentation strategies","volume":"27","author":"Buckley","year":"2001","journal-title":"Schizophr Bull"},{"key":"key\n\t\t\t\t20170508185122_bib15","doi-asserted-by":"crossref","first-page":"873","DOI":"10.4088\/JCP.08m04872gre","article-title":"Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders","volume":"71","author":"Slotema","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/00002826-200601000-00012","article-title":"Concurrent administration of clozapine and electroconvulsive therapy in clozapine-resistant schizophrenia","volume":"29","author":"Havaki-Kontaxaki","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"key\n\t\t\t\t20170508185122_bib17","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMe058298","article-title":"The choice of drugs for schizophrenia","volume":"354","author":"Davis","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170508185122_bib18","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2006.12.030","article-title":"Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial","volume":"92","author":"Freudenreich","year":"2007","journal-title":"Schizophr Res"},{"key":"key\n\t\t\t\t20170508185122_bib19","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa053222","article-title":"Clozapine alone versus clozapine and risperidone with refractory schizophrenia","volume":"354","author":"Honer","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170508185122_bib20","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/JCP.0b013e318036bfbb","article-title":"Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis","volume":"27","author":"Paton","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"key\n\t\t\t\t20170508185122_bib21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.clinthera.2007.01.002","article-title":"Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003","volume":"29","author":"Morrato","year":"2007","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t20170508185122_bib22","first-page":"395","article-title":"Risperidone as an adjunct to clozapine therapy in chronic schizophrenics","volume":"57","author":"Henderson","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib23","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1192\/bjp.171.6.569","article-title":"Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study","volume":"171","author":"Shiloh","year":"1997","journal-title":"Br J Psychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib24","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1176\/ajp.153.12.1625","article-title":"Fluoxetine augmentation of clozapine treatment in patients with schizophrenia","volume":"153","author":"Buchanan","year":"1996","journal-title":"Am J Psychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/0006-3223(96)00170-9","article-title":"Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study","volume":"40","author":"Silver","year":"1996","journal-title":"Biol Psychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/01.jcp.0000084026.22282.5f","article-title":"Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder","volume":"23","author":"Small","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"key\n\t\t\t\t20170508185122_bib27","first-page":"255","article-title":"Concurrent use of clozapine and valproate in affective and psychotic disorders","volume":"55","author":"Kando","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib28","first-page":"1","article-title":"The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychosis: a review","volume":"17","author":"Simhandl","year":"1992","journal-title":"J Psychiatry Neurosci"},{"key":"key\n\t\t\t\t20170508185122_bib29","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0006-3223(03)00524-9","article-title":"Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial","volume":"54","author":"Tiihonen","year":"2003","journal-title":"Biol Psychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib30","first-page":"484","article-title":"Bromocriptine as adjunctive therapy to clozapine in treatment-resistant schizophrenia","volume":"41","author":"Al-Semaan","year":"1996","journal-title":"Can J Psychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib31","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1176\/appi.ajp.157.5.826","article-title":"Placebo-controlled trial of glycine added to clozapine in schizophrenia","volume":"157","author":"Evins","year":"2000","journal-title":"Am J Psychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib32","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0893-133X(00)00115-9","article-title":"Mazindol treatment of negative symptoms","volume":"23","author":"Carpenter","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"key\n\t\t\t\t20170508185122_bib33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0022-3956(01)00048-6","article-title":"E-E Multicentre Study Group. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms","volume":"36","author":"Peet","year":"2002","journal-title":"J Psychiatr Res"},{"key":"key\n\t\t\t\t20170508185122_bib34","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/oxfordjournals.schbul.a033463","article-title":"Clozapine augmentation: safety and efficacy","volume":"26","author":"Chong","year":"2000","journal-title":"Schizophr Bull"},{"key":"key\n\t\t\t\t20170508185122_bib35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pnpbp.2003.09.024","article-title":"Combination of \u2018atypical\u2019 antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder","volume":"28","author":"Lerner","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib36","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1192\/bjp.181.3.184","article-title":"Clozapine-resistant schizophrenia: a positive approach","volume":"181","author":"Williams","year":"2002","journal-title":"Br J Psychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib37","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/j.0022-0337.2010.74.6.tb04904.x","article-title":"Publication bias and its implications for evidence-based clinical decision making","volume":"74","author":"Crawford","year":"2010","journal-title":"J Dent Educ"},{"key":"key\n\t\t\t\t20170508185122_bib38","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2165\/00023210-200519100-00004","article-title":"Augmentation strategies in clozapine-resistant schizophrenia","volume":"19","author":"Remington","year":"2005","journal-title":"CNS Drugs"},{"key":"key\n\t\t\t\t20170508185122_bib39","first-page":"1","article-title":"The expert consensus guideline series: treatment of schizophrenia","volume":"57","author":"Frances","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2009","journal-title":"Schizophr Bull"},{"key":"key\n\t\t\t\t20170508185122_bib41","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20170508185122_bib42","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition.","author":"American Psychiatric Association"},{"key":"key\n\t\t\t\t20170508185122_bib43","volume-title":"Practical Meta-Analysis","author":"Lipsey","year":"2001"},{"key":"key\n\t\t\t\t20170508185122_bib44","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"key\n\t\t\t\t20170508185122_bib45","doi-asserted-by":"crossref","first-page":"790","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep"},{"key":"key\n\t\t\t\t20170508185122_bib46","volume-title":"Scale for the Assessment of Positive Symptoms (SANS)","author":"Andreasen","year":"1984"},{"key":"key\n\t\t\t\t20170508185122_bib47","volume-title":"Scale for the Assessment of Negative Symptoms (SANS)","author":"Andreasen","year":"1983"},{"key":"key\n\t\t\t\t20170508185122_bib48","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1037\/1082-989X.1.2.170","article-title":"Meta-analysis of experiments with matched groups or repeated measures designs","volume":"1","author":"Dunlap","year":"1996","journal-title":"Psychol Methods"},{"key":"key\n\t\t\t\t20170508185122_bib49","first-page":"261","article-title":"Combining estimates of effect size","volume-title":"The Handbook of Research Synthesis","author":"Shadish","year":"1994"},{"key":"key\n\t\t\t\t20170508185122_bib50","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20170508185122_bib51","volume-title":"Comprehensive Meta Analysis Version 2","author":"Borenstein","year":"2005"},{"key":"key\n\t\t\t\t20170508185122_bib52","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.jcp.0000165740.22377.6d","article-title":"Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results","volume":"25","author":"Diaz","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"key\n\t\t\t\t20170508185122_bib53","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0006-3223(98)00367-9","article-title":"A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia","volume":"45","author":"Goff","year":"1999","journal-title":"Biol Psychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib54","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/01.yic.0000188216.92408.69","article-title":"Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study","volume":"21","author":"Kreinin","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"key":"key\n\t\t\t\t20170508185122_bib55","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.4088\/JCP.v66n0808","article-title":"Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial","volume":"66","author":"Tiihonen","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib56","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.schres.2007.02.009","article-title":"The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study","volume":"93","author":"Zoccali","year":"2007","journal-title":"Schizophr Res"},{"key":"key\n\t\t\t\t20170508185122_bib57","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0269881108089816","article-title":"Topiramate add-on treatment in schizophrenia: a randomized, double-blind, placebo-controlled clinical trial","volume":"23","author":"Afshar","year":"2009","journal-title":"J Psychopharmacol"},{"key":"key\n\t\t\t\t20170508185122_bib58","article-title":"Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study","author":"Muscatello","journal-title":"J Psychopharmacol."},{"key":"key\n\t\t\t\t20170508185122_bib59","first-page":"696","article-title":"A randomized, placebo-controlled clinical trial of combined citalopram and clozapine in the treatment of negative symptoms of schizophrenia","volume":"20","author":"Lan","year":"2006","journal-title":"Chin Ment Health J"},{"key":"key\n\t\t\t\t20170508185122_bib60","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00004850-200403000-00003","article-title":"The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study","volume":"19","author":"Zoccali","year":"2004","journal-title":"Int Clin Psychopharmacol"},{"key":"key\n\t\t\t\t20170508185122_bib61","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hup.1017","article-title":"Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial","volume":"24","author":"Berk","year":"2009","journal-title":"Hum Psychopharmacol"},{"key":"key\n\t\t\t\t20170508185122_bib62","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.biopsych.2004.06.029","article-title":"Placebo- controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia","volume":"56","author":"Kremer","year":"2004","journal-title":"Biol Psychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib63","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4088\/JCP.v66n0109","article-title":"A Double-Blind Controlled Study of Adjunctive Treatment With Risperidone in Schizophrenic Patients Partially Responsive to Clozapine: efficacy and Safety","volume":"66","author":"Anil Yagcioglu","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib64","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1176\/appi.ajp.162.1.130","article-title":"A Clozapine Augmented With Risperidone in the Treatment of Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Trial","volume":"162","author":"Josiassen","year":"2005","journal-title":"Am J Psychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib65","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/jcp.0b013e31815abf34","article-title":"Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials","volume":"27","author":"Goff","year":"2007","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"key\n\t\t\t\t20170508185122_bib66","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4088\/JCP.v69n0505","article-title":"Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: An 8-week, randomized, double-blind, placebo-controlled trial","volume":"69","author":"Chang","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"key\n\t\t\t\t20170508185122_bib67","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1017\/S1461145710000490","article-title":"Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial","volume":"13","author":"Fleischhacker","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"issue":"suppl. 4","key":"key\n\t\t\t\t20170508185122_bib68","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0924-977X(06)70524-7","article-title":"Haloperidol in combination with clozapine in treatment-refractory patients with schizophrenia","volume":"16","author":"Mossaheb","year":"2006","journal-title":"Eur Neuropsychopharmacol"},{"key":"key\n\t\t\t\t20170508185122_bib69","article-title":"July 21, 2010. Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine","author":"Weiner","journal-title":"Neuropsychopharmacol"},{"key":"key\n\t\t\t\t20170508185122_bib70","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/00004714-200110000-00005","article-title":"A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia","volume":"21","author":"Goff","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"key\n\t\t\t\t20170508185122_bib71","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1176\/ajp.156.11.1822","article-title":"D-serine added to clozapine for the treatment of schizophrenia","volume":"156","author":"Tsai","year":"1999","journal-title":"Am J Psychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib72","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1176\/ajp.156.1.145","article-title":"Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia","volume":"156","author":"Potkin","year":"1999","journal-title":"Am J Psychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib73","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.biopsych.2006.04.005","article-title":"Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia","volume":"60","author":"Lane","year":"2006","journal-title":"Biol Psychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib74","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1055\/s-2007-993209","article-title":"Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial","volume":"41","author":"Assion","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"key\n\t\t\t\t20170508185122_bib75","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/schbul\/sbp163","article-title":"Sulpiride augmentation for schizophrenia","volume":"36","author":"Wang","year":"2010","journal-title":"Schizophr Bull"},{"key":"key\n\t\t\t\t20170508185122_bib76","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1600-0447.2009.01367.x","article-title":"Augmentation of clozapine with a second antipsychotic\u2014a meta-analysis of randomized, placebo-controlled studies","volume":"119","author":"Taylor","year":"2009","journal-title":"Acta Psychiatr Scand"},{"key":"key\n\t\t\t\t20170508185122_bib77","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/schbul\/sbn030","article-title":"Does the addition of a second antipsychotic drug improve clozapine treatment?","volume":"35","author":"Barbui","year":"2009","journal-title":"Schizophr Bull"},{"key":"key\n\t\t\t\t20170508185122_bib78","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s00406-006-0643-9","article-title":"Risperidone augmentation of clozapine: a critical review","volume":"256","author":"Kontaxakis","year":"2006","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"key\n\t\t\t\t20170508185122_bib79","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.schres.2009.01.002","article-title":"The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis","volume":"109","author":"Tiihonen","year":"2009","journal-title":"Schizophr Res"},{"key":"key\n\t\t\t\t20170508185122_bib80","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jclinepi.2004.02.018","article-title":"EU-PSI project. Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time","volume":"57","author":"Trikalinos","year":"2004","journal-title":"J Clin Epidemiol"}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/38\/5\/1003\/16704146\/sbr004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T21:21:36Z","timestamp":1686000096000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-lookup\/doi\/10.1093\/schbul\/sbr004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,21]]},"references-count":80,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2011,3,21]]},"published-print":{"date-parts":[[2012,9]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbr004","relation":{},"ISSN":["1745-1701","0586-7614"],"issn-type":[{"value":"1745-1701","type":"electronic"},{"value":"0586-7614","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3,21]]}}}